FBRX
Forte Biosciences, Inc. [FBRX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
FBRX Stock Summary
Top 10 Correlated Stocks
FBRX
In the News
FBRX Financial details
Company Rating
Neutral
Market Cap
26.32M
Income
-31.37M
Revenue
0
Book val./share
0.97
Cash/share
1.02
Dividend
-
Dividend %
-
Employees
9
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-1.06
Forward P/E
-
PEG
-0.24
P/S
-
P/B
0.8
P/C
0.76
P/FCF
-1.36
Quick Ratio
6.18
Current Ratio
6.3
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.16
EPS next Y
-
EPS next Q
-
EPS this Y
25%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-38.46%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
69.94%
Inst Trans
4.28%
ROA
-63%
ROE
-89%
ROC
-0.77%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.38-1.15
52W High
-
52W Low
-
RSI
59
Rel Volume
1.4
Avg Volume
34.26K
Volume
47.97K
Perf Week
6.85%
Perf Month
1.38%
Perf Quarter
65.89%
Perf Half Y
34.48%
-
-
-
-
Beta
1.655
-
-
Volatility
0.02%, 0.03%
Prev Close
5.41%
Price
0.78
Change
6.85%
FBRX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -1.93 | -10.67 | -1.55 | -0.8 | -1 | |
| Operating cash flow per share | -1.31 | -2.5 | -1.19 | -0.47 | -0.91 | |
| Free cash flow per share | -1.39 | -2.5 | -1.19 | -0.47 | -0.91 | |
| Cash per share | 9.38 | 7.99 | 3.01 | 2.36 | 1.18 | |
| Book value per share | -2.26 | 8.01 | 2.97 | 2.23 | 1.12 | |
| Tangible book value per share | -2.26 | 8.01 | 2.97 | 2.23 | 1.12 | |
| Share holders equity per share | -2.26 | 8.01 | 2.97 | 2.23 | 1.12 | |
| Interest debt per share | 2.35 | 0 | 0 | 0 | 0 | |
| Market cap | 16.87M | 267.94M | 29.89M | 17.38M | 25.94M | |
| Enterprise value | 18.7M | 209.17M | -12.15M | -23.72M | 13.98M | |
| P/E ratio | -4.15 | -3.41 | -1.38 | -1.25 | -0.82 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -6.09 | -14.54 | -1.79 | -2.12 | -0.9 | |
| PFCF ratio | -5.75 | -14.54 | -1.79 | -2.12 | -0.9 | |
| P/B Ratio | -3.54 | 4.54 | 0.72 | 0.45 | 0.73 | |
| PTB ratio | -3.54 | 4.54 | 0.72 | 0.45 | 0.73 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -4.61 | 11.69 | 0.57 | 1.71 | -0.43 | |
| EV to operating cash flow | -6.75 | -11.35 | 0.73 | 2.9 | -0.49 | |
| EV to free cash flow | -6.38 | -11.35 | 0.73 | 2.9 | -0.49 | |
| Earnings yield | -0.24 | -0.29 | -0.73 | -0.8 | -1.21 | |
| Free cash flow yield | -0.17 | -0.07 | -0.56 | -0.47 | -1.11 | |
| Debt to equity | -1.84 | 0 | 0 | 0 | 0 | |
| Debt to assets | 1.15 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | -0.45 | -3.29 | 1.96 | 2.96 | 0.37 | |
| Current ratio | 3.93 | 26.52 | 24.19 | 13.06 | 10.45 | |
| Interest coverage | 1.06 | 0 | 0 | 817.41 | 0 | |
| Income quality | 0.68 | 0.4 | 0.77 | 0.59 | 0.91 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.06 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -14.7 | 0 | 0 | 0 | -9.78 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 9.91 | 43.87 | 10.2 | 6.33 | 5.01 | |
| ROIC | -0.51 | 0.51 | -0.52 | -0.36 | -0.92 | |
| Return on tangible assets | -0.53 | -1.28 | -0.5 | -0.33 | -0.81 | |
| Graham Net | 3.48 | 7.68 | 2.88 | 2.18 | 1.06 | |
| Working capital | 5.59M | 57.64M | 40.76M | 38.33M | 34.66M | |
| Tangible asset value | -4.77M | 58.98M | 41.55M | 38.82M | 35.31M | |
| Net current asset value | -4.92M | 57.64M | 40.76M | 38.33M | 34.66M | |
| Invested capital | -1.84 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 2.49M | 1.4M | 1.09M | 1.05M | 1.29M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 52.05K | 8.38K | 9.59K | 0 | 57.75K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.01 | 0.04 | 0.04 | 0 | 0.01 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.85 | -1.33 | -0.52 | -0.36 | -0.89 | |
| Capex per share | -0.08 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.23 | -0.32 | -0.42 | -0.26 | -0.16 | |
| Operating cash flow per share | -0.14 | -0.25 | -0.26 | -0.24 | -0.25 | |
| Free cash flow per share | -0.14 | -0.25 | -0.26 | -0.24 | -0.25 | |
| Cash per share | 1.96 | 1.71 | 1.45 | 1.22 | 1.02 | |
| Book value per share | 1.85 | 1.57 | 1.18 | 1.07 | 0.97 | |
| Tangible book value per share | 1.85 | 1.57 | 1.18 | 1.07 | 0.97 | |
| Share holders equity per share | 1.85 | 1.57 | 1.18 | 1.07 | 0.97 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 21M | 21.22M | 21.89M | 25.07M | 29.86M | |
| Enterprise value | -20.1M | -14.69M | 1.45M | 3.92M | 17.9M | |
| P/E ratio | -1.08 | -0.8 | -0.62 | -0.63 | -1.27 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -7.26 | -4.08 | -4 | -2.77 | -3.33 | |
| PFCF ratio | -7.26 | -4.08 | -4 | -2.75 | -3.32 | |
| P/B Ratio | 0.54 | 0.64 | 0.88 | 0.62 | 0.85 | |
| PTB ratio | 0.54 | 0.64 | 0.88 | 0.62 | 0.85 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 4.07 | 2.14 | -0.16 | -0.38 | -2.81 | |
| EV to operating cash flow | 6.95 | 2.82 | -0.26 | -0.43 | -2 | |
| EV to free cash flow | 6.95 | 2.82 | -0.26 | -0.43 | -1.99 | |
| Earnings yield | -0.23 | -0.31 | -0.41 | -0.4 | -0.2 | |
| Free cash flow yield | -0.14 | -0.25 | -0.25 | -0.36 | -0.3 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 8.32 | 5.24 | 2.26 | 2.07 | 1.88 | |
| Current ratio | 13.06 | 9.65 | 4.88 | 6.3 | 10.45 | |
| Interest coverage | -823.17 | 67.21 | 0 | 0 | 0 | |
| Income quality | 0.59 | 0.77 | 0.62 | 0.91 | 1.53 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0.01 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | -23.67 | -2.83 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 3.11 | 3.34 | 3.35 | 2.51 | 1.88 | |
| ROIC | -0.13 | -0.2 | -0.36 | -0.25 | -0.18 | |
| Return on tangible assets | -0.12 | -0.18 | -0.29 | -0.21 | -0.15 | |
| Graham Net | 1.81 | 1.53 | 1.15 | 1.02 | 0.92 | |
| Working capital | 38.33M | 32.51M | 24.45M | 39.63M | 34.66M | |
| Tangible asset value | 38.82M | 32.95M | 24.88M | 40.41M | 35.31M | |
| Net current asset value | 38.33M | 32.51M | 24.45M | 39.63M | 34.66M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 1.17M | 1.25M | 2.17M | 4.18M | 3.39M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 160.62K | 21.36K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.13 | -0.2 | -0.36 | -0.25 | -0.17 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
FBRX Frequently Asked Questions
What is Forte Biosciences, Inc. stock symbol ?
Forte Biosciences, Inc. is a US stock , located in Dallas of Tx and trading under the symbol FBRX
What is Forte Biosciences, Inc. stock quote today ?
Forte Biosciences, Inc. stock price is $0.78 today.
Is Forte Biosciences, Inc. stock public?
Yes, Forte Biosciences, Inc. is a publicly traded company.
Company Profile
- Volume Average 34.26K
- Market Capitalization 26.32M
- Employee 9
- CEO Dr. Paul A. Wagner Ph.D.
- Headquarters Dallas,TX,US
- IPO Date 2017-04-13
-
Website
https://www.fortebiorx.com 
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
